153 results match your criteria Injectable Bulking Agents for Incontinence


Artificial urinary sphincter: current status and future directions.

Authors:
Culley C Carson

Asian J Androl 2020 Mar-Apr;22(2):154-157

Department of Urology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Urge urinary incontinence (UUI) is one of the most troublesome complications of surgery of the prostate whether for malignancy or benign conditions. For many decades, there have been attempts to reduce the morbidity of this outcome with variable results. Since its development in the 1970s, the artificial urinary sphincter (AUS) has been the "gold standard" for treatment of the most severe cases of UUI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/aja.aja_5_20DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155799PMC

Management of erectile dysfunction and LUTS/incontinence: the two most common, long-term side effects of prostate cancer treatment.

Can J Urol 2020 Feb;27(1S1):17-24

Division of Urology, University Health Network, University of Toronto, Toronto, Ontario, Canada.

The two major long-term concerns associated with different options for the management of prostate cancer, (including surgery, radiotherapy, brachytherapy, cryotherapy, HIFU, etc.) include difficulties with lower urinary tract symptoms (LUTS) and/or erectile dysfunction. LUTS can be in the form of stress urinary incontinence (SUI), urge urinary incontinence (UUI), frequency/urgency, and/or voiding difficulties. Read More

View Article

Download full-text PDF

Source
February 2020

Lower Urinary Tract and Bowel Dysfunction in Neurologic Disease.

Continuum (Minneap Minn) 2020 02;26(1):178-199

Purpose Of Review: This article provides an overview of the clinical presentation, investigations, and treatment options for lower urinary tract and bowel dysfunction in patients with neurologic diseases.

Recent Findings: The site of the neurologic lesion influences the pattern of lower urinary tract dysfunction. Antimuscarinic agents are first-line management for urinary incontinence; however, the side effect profile should be considered when prescribing them. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/CON.0000000000000824DOI Listing
February 2020

Middle-term Outcomes of Gatekeeper Implantation for Fecal Incontinence.

Dis Colon Rectum 2020 04;63(4):514-519

Department of Medical, Surgical, Neurologic, Metabolic and Aging Sciences, General, Mini-invasive and Obesity Surgery Unit, University of Campania "Luigi Vanvitelli," Naples, Italy.

Background: Intersphincteric injectable bulking agents are one of the current treatment options for fecal incontinence, failing behavioral and medical therapy. Gatekeeper showed promising short-term results, but long-term outcomes are unknown.

Objective: The purpose of this study was to clinically evaluate a prospective cohort of fecal incontinence patients up to 36 months after implantation of Gatekeeper. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DCR.0000000000001559DOI Listing

Regenerative medicine and injection therapies in stress urinary incontinence.

Nat Rev Urol 2020 03 23;17(3):151-161. Epub 2020 Jan 23.

Royal Hallamshire Hospital, Glossop Road, Sheffield, UK.

Stress urinary incontinence (SUI) is a common and bothersome condition. Anti-incontinence surgery has high cure rates, but concerns about mesh tapes have resulted in the resurgence of surgical procedures that involve increased abdominopelvic dissection and morbidity. Injection therapy with urethral bulking agents or stem cell formulations have been developed as minimally invasive alternatives. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41585-019-0273-4DOI Listing

Urinary Incontinence in Women: Evaluation and Management.

Am Fam Physician 2019 09;100(6):339-348

Winn Army Community Hospital, Fort Stewart, GA, USA.

Urinary incontinence is a common problem among women worldwide, resulting in a substantial economic burden and decreased quality of life. The Women's Preventive Services Initiative is the only major organization that recommends annual screening for urinary incontinence in all women despite low to insufficient evidence regarding effectiveness and accuracy of methods. No other major organization endorses screening. Read More

View Article

Download full-text PDF

Source
September 2019
6 Reads

The use of urethral bulking injections in post-prostatectomy stress urinary incontinence: A narrative review of the literature.

Neurourol Urodyn 2019 11 20;38(8):2060-2069. Epub 2019 Aug 20.

Department of Urology, St George's NHS Foundation Trust, London, UK.

Aims: Post-prostatectomy stress urinary incontinence (PPI) is a common condition with significant impact on patient quality of life. With rising numbers of prostatectomies performed, recognition of incontinence during survivorship care is growing. With increasing hesitance of the use of suburethral mesh in females, urethral bulking injections in this patient population as a minimally invasive alternative to surgery are evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/nau.24143DOI Listing
November 2019

Effectiveness of Autologous Fat Graft in Treating Fecal Incontinence.

Ann Coloproctol 2019 Jun 30;35(3):144-151. Epub 2019 Jun 30.

Department of Surgery, Busan Hangun Hospital, Busan, Korea.

Purpose: The most common risk factor for fecal incontinence (FI) is obstetric injury. FI affects 1.4%-18% of adults. Read More

View Article

Download full-text PDF

Source
http://coloproctol.org/journal/view.php?doi=10.3393/ac.2018.
Publisher Site
http://dx.doi.org/10.3393/ac.2018.09.15DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6625772PMC
June 2019
9 Reads

Complications of urethral bulking therapy for female stress urinary incontinence.

Neurourol Urodyn 2019 08 8;38 Suppl 4:S12-S20. Epub 2019 May 8.

Department of Urology, University of Illinois at Chicago (UIC), Chicago, Illinois.

Aims: To review, report, and discuss the complications associated with urethral bulking therapy in female stress urinary incontinence.

Methods: An extensive nonsystematic literature review on complications associated with injectable bulking agents used in the clinical practice was conducted. We reviewed articles published in English and indexed in the PubMed, Embase, and Google Scholar databases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/nau.23877DOI Listing
August 2019
7 Reads

Surgery for urinary incontinence in women: Report from the 6th international consultation on incontinence.

Neurourol Urodyn 2019 02 4;38(2):825-837. Epub 2018 Dec 4.

Department of Urology, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.

Urinary incontinence is a prevalent condition worldwide and causes a tremendous impact on a woman's quality of life. While conservative and non-surgical therapies are options for treatment, surgery for stress urinary incontinence (SUI) is common. Options include colposuspension, slings (pubovaginal and midurethral), and periurethral bulking. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/nau.23895DOI Listing
February 2019
23 Reads

Injection of Urethral Bulking Agents.

Urol Clin North Am 2019 Feb;46(1):1-15

Urinary Tract and Pelvic Reconstruction, Department of Urology, MD Anderson Cancer Center, Unit 1373, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Electronic address:

Urethral injection is a safe and minimally invasive method of treating female stress urinary incontinence with multiple bulking agents currently commercially available. Although there are numerous studies that demonstrate efficacy, long-term success is not yet proven. This article aims to describe the mechanism of action and properties of various agents, patient selection factors, available techniques for injection, outcomes of urethral injections, and complications associated with the procedure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ucl.2018.08.012DOI Listing
February 2019
39 Reads

Can Urethral Bulking Agents Salvage Failed Slings?

Urology 2019 Feb 7;124:78-82. Epub 2018 Nov 7.

Michigan Medicine University of Michigan, Ann Arbor, MI.

Objective: To evaluate the efficacy of urethral bulking agents for stress urinary incontinence (SUI) in the setting of prior failed sling.

Methods: This is a retrospective review of patients who underwent urethral bulking agent injections for a primary complaint of SUI following prior failed sling surgery. The outcomes assessed were patient reported improvement, need for further interventions for incontinence and validated questionnaires. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00904295183105
Publisher Site
http://dx.doi.org/10.1016/j.urology.2018.09.019DOI Listing
February 2019
27 Reads

Retrospective analysis after endoscopic urethral injections of glutaraldehyde-cross-linked-collagen or dextranomer/hyaluronic acid copolymer in bitches with urinary incontinence.

J Small Anim Pract 2019 Feb 2;60(2):96-101. Epub 2018 Nov 2.

EVIDENSIA Tierärztliche Klinik für Kleintiere Norderstedt GmbH, 22850 Norderstedt, Germany.

Objectives: To evaluate the outcome of endoscopic injection of two different bulking agents, glutaraldehyde cross-linked collagen and dextranomer/hyaluronic acid copolymer into the urethral submucosa in female dogs with urinary incontinence caused by urethral sphincter mechanism incompetence.

Materials And Methods: Retrospective review of records and follow-up communication with owners of dogs that received an endoscopically guided urethral bulking procedure. In each dog, either cross-linked collagen (2007 to 2011) or dextranomer/hyaluronic acid copolymer (2012 to 2015) was used. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jsap.12949
Publisher Site
http://dx.doi.org/10.1111/jsap.12949DOI Listing
February 2019
16 Reads

Efficacy and safety of polydimethylsiloxane injection (Macroplastique ) for the treatment of female stress urinary incontinence: results of a series of 85 patients with ≥3 years of follow-up.

BJU Int 2019 02 16;123(2):353-359. Epub 2018 Oct 16.

Department of Obstetrics and Gynecology, University of Insubria, Varese, Italy.

Objective: To assess the long-term efficacy and safety of polydimethylsiloxane injection (Macroplastique , Cogentix Medical, Orangeburg, New York, USA) for the treatment of female stress urinary incontinence (SUI), with a minimum follow-up of 3 years.

Patients And Methods: This is an observational analytical prospective cohort study conducted in a single uro-gynaecological unit. All consecutive women with urodynamically confirmed pure SUI treated with the Macroplastique procedure, were included. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bju.14550
Publisher Site
http://dx.doi.org/10.1111/bju.14550DOI Listing
February 2019
23 Reads

Urolastic®, a new bulking agent for treatment of stress urinary incontinence: a systematic review and meta-analysis.

Int Urogynecol J 2018 09 23;29(9):1239-1247. Epub 2018 Jun 23.

Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Viale San Pietro 12, 07100, Sassari, Italy.

Introduction And Hypothesis: The aim of the present systematic review and meta-analysis was to assess the effectiveness and safety of injections of the new bulking agent Urolastic® in the treatment of patients with stress urinary incontinence (SUI).

Methods: A systematic search was carried out to select observational and experimental studies on Urolastic® in female patients with SUI. Three different databases, Pubmed, the Cochrane Central Register of Controlled Trials, and Scopus, were used to retrieve scientific articles published from their inception to 31 January 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00192-018-3703-6DOI Listing
September 2018
36 Reads

CT and MR Imaging Features of Artificial Urinary Sphincters, Penile Prostheses, and Other Devices in the Male Lower Genitourinary Tract.

Radiographics 2018 May-Jun;38(3):794-805

From PENRAD Imaging and Colorado Springs Radiologists, Colorado Springs, Colo (E.T.C.); and Departments of Radiology (P.R., E.S.S.) and Urology (W.I.J.), Hospital of the University of Pennsylvania, 3400 Spruce St, MRI 1 Founders, Philadelphia, PA 19104-4283.

Urinary incontinence and erectile dysfunction are relatively common conditions in the aging male population. Surgical interventions for urinary incontinence include placement of an artificial urinary sphincter (AUS), perineal sling, or sacral nerve stimulator and injections of periurethral bulking agents. Erectile dysfunction can be treated surgically with placement of a penile prosthesis. Read More

View Article

Download full-text PDF

Source
http://pubs.rsna.org/doi/10.1148/rg.2018170087
Publisher Site
http://dx.doi.org/10.1148/rg.2018170087DOI Listing
October 2018
35 Reads

Face, Content, and Construct Validations of Endoscopic Needle Injection Simulator for Transurethral Bulking Agent in Treatment of Stress Urinary Incontinence.

J Surg Educ 2018 Nov 3;75(6):1673-1678. Epub 2018 May 3.

Department of Urology, Division of Female Urology, Pelvic Reconstruction Surgery & Voiding Dysfunction University of California, Irvine, California. Electronic address:

Introduction And Objectives: Endoscopic injection of urethral bulking agents is an office procedure that is used to treat stress urinary incontinence secondary to internal sphincteric deficiency. Validation studies important part of simulator evaluation and is considered important step to establish the effectiveness of simulation-based training. The endoscopic needle injection (ENI) simulator has not been formally validated, although it has been used widely at University of California, Irvine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jsurg.2018.04.011DOI Listing
November 2018
7 Reads

Achieving urinary continence in cloacal exstrophy: The surgical cost.

J Pediatr Surg 2018 Oct 24;53(10):1937-1941. Epub 2018 Feb 24.

Robert D. Jeffs Division of Pediatric Urology, The James Buchanan Brady Urological Institutions, The Johns Hopkins Hospital, Johns Hopkins Medical Institutions, Charlotte Bloomberg Children's Hospital, Baltimore, MD, USA. Electronic address:

Introduction: Cloacal exstrophy (CE) is a severe midline congenital abnormality that requires numerous surgical corrections to achieve an acceptable quality of life. Candidates for urinary continence undergo multiple procedures, most often continent bladder diversions, to become socially dry. Here, the authors investigate the number of genitourinary interventions that patients with CE undergo to attain urinary continence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpedsurg.2018.02.055DOI Listing
October 2018
13 Reads

Does intraoperative success predict outcome in the treatment of urethral sphincter insufficiency with bulking agent?

J Pediatr Urol 2018 04 31;14(2):173.e1-173.e5. Epub 2018 Jan 31.

Department of Pediatric Surgery, Children's Hospital, University of Helsinki, Helsinki, Finland. Electronic address:

Introduction: Sphincter insufficiency is mostly associated with neurogenic and some structural abnormalities in the pediatric population. As a mini-invasive treatment, urethral bulking agents have been used to treat this problem.

Objective: The aim was to evaluate if technical success, defined as intraoperative increase in abdominal leak point pressure (ALPP), predicts the outcome of the treatment of sphincter insufficiency with urethral bulking agent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpurol.2017.10.020DOI Listing
April 2018
10 Reads

Microfluidic production of bioactive fibrin micro-beads embedded in crosslinked collagen used as an injectable bulking agent for urinary incontinence treatment.

Acta Biomater 2018 02 29;67:156-166. Epub 2017 Nov 29.

Laboratory of Stem Cell Bioengineering, Institute of Bioengineering, School of Life Sciences and School of Engineering, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland. Electronic address:

Endoscopic injection of bulking agents has been widely used to treat urinary incontinence, often due to urethral sphincter complex insufficiency. The aim of the study was to develop a novel injectable bioactive collagen-fibrin bulking agent restoring long-term continence by functional muscle tissue regeneration. Fibrin micro-beads were engineered using a droplet microfluidic system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.actbio.2017.11.034DOI Listing
February 2018
9 Reads

Effectiveness of Bulking Agent (Solesta) Therapy in Fecal Incontinence in Patients Refractory to Conventional Therapies.

Am J Med Sci 2017 11 5;354(5):476-479. Epub 2017 Sep 5.

Division of Gastroenterology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine, El Paso, Texas. Electronic address:

Background: Fecal incontinence is a problem that imposes considerable socioeconomic consequences. Despite many medical therapies, unmet needs remain. A new treatment option is a biocompatible bulking agent (Solesta) administered by submucosal injection in the distal rectum. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjms.2017.09.001DOI Listing
November 2017
18 Reads

Complications of Urethral Bulking Agents for Stress Urinary Incontinence: An Extensive Review Including Case Reports.

Female Pelvic Med Reconstr Surg 2018 Nov/Dec;24(6):392-398

Department of Urology, University of Illinois, Chicago, IL.

Objectives: Stress urinary incontinence in women is a common problem that significantly impacts quality of life. Periurethral injection of urethral bulking agents (UBAs) is a simple, noninvasive, and cost-effective treatment. However, complications associated with UBA are often underappreciated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/SPV.0000000000000495DOI Listing
April 2019
9 Reads

Aktuelle Behandlungskonzepte bei Belastungsinkontinenz.

Praxis (Bern 1994) 2017 Jul;106(15):829-836

1 Blasen- und Beckenbodenzentrum, Frauenklinik, Kantonsspital Frauenfeld.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1024/1661-8157/a002743DOI Listing
July 2017
19 Reads

Urethral injection therapy for urinary incontinence in women.

Cochrane Database Syst Rev 2017 07 25;7:CD003881. Epub 2017 Jul 25.

Department of Urology, Sunderland Royal Hospital, Kayll Road, Sunderland, Tyne & Wear, UK, SR4 7TP.

Background: Urinary incontinence imposes a significant health and economic burden to society. Periurethral or transurethral injection of bulking agents is a minimally invasive surgical procedure used as one the surgical treatments of stress urinary incontinence (SUI) in adult women.

Objectives: To assess the effects of periurethral or transurethral injection therapy on the cure or improvement of urinary incontinence in women. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD003881.pub4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6483304PMC
July 2017
26 Reads

Radiographic Misdiagnoses After Periurethral Bulking Agents.

Female Pelvic Med Reconstr Surg 2018 Jul/Aug;24(4):312-314

William Beaumont School of Medicine, Oakland University, Rochester, MI.

Objectives: Injectable urethral bulking agents are commonly used to manage stress urinary incontinence. Urologic or other symptoms may prompt pelvic imaging at a later date, when bulking agents may be visualized and incorrectly interpreted. Our goal was to evaluate the incidence of misdiagnosis and which pathologies were the most common misinterpretations and their frequency. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/SPV.0000000000000440DOI Listing
March 2019
83 Reads

Periurethral bulking agents for female stress urinary incontinence in Canada.

Can Urol Assoc J 2017 Jun;11(6Suppl2):S152-S154

Section of Urology, Department of Surgery, University of Calgary, Calgary, AB, Canada.

Urethral bulking aims to improve urethral mucosal coaptation, and thus outlet resistance, in an effort to limit stress-induced leakage. While efforts have been made to employ bulking agents to treat stress urinary incontinence (SUI) for more than 100 years, we remain wanting for the perfect injectable. Regardless of the agent studied, efficacy is modest at best, repeat injections are the norm, and long-term followup is conspicuously lacking. Read More

View Article

Download full-text PDF

Source
http://www.cuaj.ca/index.php/journal/article/view/4612
Publisher Site
http://dx.doi.org/10.5489/cuaj.4612DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461150PMC
June 2017
68 Reads

Management of patients with stress urinary incontinence after failed midurethral sling.

Can Urol Assoc J 2017 Jun;11(6Suppl2):S143-S146

Department of Urology, Dalhousie University, Halifax, NS; Canada.

Surgical failure rates after midurethral sling (MUS) procedures are variable and range from approximately 8-57% at five years of followup. The disparity in long-term failure rates is explained by a lack of long-term followup and lack of a clear definition of what constitutes failure. A recent Cochrane review illustrates that no high-quality data exists to recommend or refute any of the different management strategies for recurrent or persistent stress urinary incontinence (SUI) after failed MUS surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5489/cuaj.4610DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461148PMC
June 2017
31 Reads

Midterm outcomes of injectable bulking agents for fecal incontinence: a systematic review and meta-analysis.

Tech Coloproctol 2017 Mar 1;21(3):203-210. Epub 2017 Mar 1.

Department of Colorectal Surgery, Korea University College of Medicine Ansan Hospital, Gojan 1-dong, Danwon-gu, Ansan-si, Gyeonggi-do, Republic of Korea.

Background: Various bulking agents have been used to treat fecal incontinence. While short-term outcomes are attractive, there is still a lack of long-term data. The aim of this systematic review and meta-analysis was to investigate the midterm outcomes of treatment with injectable bulking agents and to identify predictive factors for improvement in incontinence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10151-017-1593-0DOI Listing
March 2017
4 Reads

Intraurethral bulking agents for the management of female stress urinary incontinence: a systematic review.

Int Urogynecol J 2017 Sep 21;28(9):1275-1284. Epub 2017 Feb 21.

Department of Urology, Watford General Hospital, Vicarage Road, Watford, WD80 0HB, UK.

Introduction And Hypothesis: The object of this review was to assess the efficacy and safety of urethral bulking agents (UBA), principally Macroplastique and Bulkamid, in the treatment of female stress urinary incontinence (SUI).

Methods: MEDLINE® and EMBASE® databases were systematically searched up to June 2016. Year of publication, study type, outcome measures, urodynamics before and after the procedure, number of participants, procedure complications, proportion requiring repeat injections or surgical procedures, frequency of follow-up, and results were analysed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00192-017-3278-7DOI Listing
September 2017
5 Reads

Sacral neuromodulation compared with injection of bulking agents for faecal incontinence following obstetric anal sphincter injury - a randomized controlled trial.

Colorectal Dis 2017 May;19(5):O134-O144

Department of Gastroenterological Surgery, University Hospital of North Norway, Tromsoe, Norway.

Aim: The purpose of this trial was to compare the effectiveness of sacral neuromodulation (SNM) with a submucosal injection of collagen (Permacol®) in women with faecal incontinence following obstetric anal sphincter injury (OASIS).

Method: This single-blinded randomized controlled trial at two hospital units in Norway included women with faecal incontinence following OASIS. Eligible women who had had a successful percutaneous nerve evaluation were randomly assigned to SNM or Permacol®. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/codi.13632DOI Listing
May 2017
23 Reads

Para-Urethral Injections with Urolastic® for Treatment of Female Stress Urinary Incontinence: Subjective Improvement and Safety.

Urol Int 2017 3;99(1):91-97. Epub 2017 Feb 3.

Department of Urology, Radboud University Medical Centre, Nijmegen, The Netherlands.

Introduction: Female stress urinary incontinence (SUI) is often treated surgically. Urethral bulking agents are a minimally invasive alternative, especially in patients suffering from intrinsic sphincter deficiency, but often with limited long-term efficacy. Urolastic® is a non-deformable, non-resorbable silicone elastomer that is used as an injectable. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000452450DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5637293PMC
May 2018
44 Reads

Nonabsorbable urethral bulking agent - clinical effectiveness and late complications rates in the treatment of recurrent stress urinary incontinence after 2 years of follow-up.

Eur J Obstet Gynecol Reprod Biol 2016 Dec 26;207:68-72. Epub 2016 Oct 26.

2nd Department of Gynecology, Medical University of Lublin, ul. Jaczewskiego 8, 20-954 Lublin, Poland.

Objective: Those patients who failed to achieve continence after a procedure aimed to correct it, require a special attitude and precise management due to the sophisticated anatomical and functional field of interest. The purpose of the present study was to assess long-term clinical efficacy and evaluate the frequency and severity of any complications related to recurrent stress urinary incontinence treatment with a non-absorbable bulking agent periurethral injections.

Study Design: Between February 2012-September 2013, 66 patients with recurrent stress urinary incontinence were treated with Urolastic in the tertiary referral gynecologic department. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejogrb.2016.10.011DOI Listing
December 2016
24 Reads

Outcomes of Surgical Management in Patients with Stress Urinary Incontinence and/or Neovesicovaginal Fistula after Orthotopic Neobladder Diversion.

J Urol 2016 11 8;196(5):1478-1483. Epub 2016 Jun 8.

Department of Urology, Mayo Clinic, Rochester, Minnesota. Electronic address:

Purpose: To our knowledge there are no guidelines for the evaluation and management of incontinence in women with an orthotopic neobladder. We propose a treatment algorithm based on our experience with treating this patient population.

Materials And Methods: We identified women in whom orthotopic neobladder diversion and surgery for incontinence were performed from January 1, 1995 to January 1, 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2016.06.009DOI Listing
November 2016
34 Reads

The efficacy and safety of urethral injection therapy for urinary incontinence in women: a systematic review.

Clinics (Sao Paulo) 2016 Feb;71(2):94-100

Disciplina de Ginecologia, Divisão de Uroginecologia, Departamento de Obstetrícia e Ginecologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP), São Paulo/SP, Brazil.

To evaluate the efficacy and safety of different bulking agents for treating urinary incontinence in women, a systematic review including only randomized controlled trials was performed. The subjects were women with urinary incontinence. The primary outcomes were clinical and urodynamic parameters. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6061/clinics/2016(02)08DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760362PMC
February 2016
26 Reads

Transanal submucosal polyacrylamide gel injection treatment of anal incontinence: a randomized controlled trial.

Acta Obstet Gynecol Scand 2016 May 14;95(5):528-33. Epub 2016 Mar 14.

Department of Clinical Sciences, Karolinska Institute Danderyd Hospital, Danderyd, Sweden.

Introduction: The efficacious and safe use of transurethral injections of polyacrylamide hydrogel (Bulkamid(®)) in women with stress urinary incontinence suggests that it may be suitable also for treatment of anal incontinence. We aimed to determine the effectiveness and safety of polyacrylamide hydrogel when used as a transanal submucosal bulking agent in women with anal incontinence.

Materials And Methods: Thirty women with a diagnosis of anal incontinence and a Cleveland Clinic Incontinence Score (CCIS) >10 were randomized to three different techniques of transanal submucosal injections using polyacrylamide hydrogel. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/aogs.12866DOI Listing
May 2016
14 Reads

Bulking agents - an analysis of 500 cases and review of the literature.

Clin Exp Obstet Gynecol 2016;43(5):666-672

Introduction: Stress urinary incontinence (SUI) is common, impacts women's quality of life and generates high costs. Physiotherapy is the first line therapy and if it fails, suburethral slings are currently the gold standard in SUI surgery. Bulking agents injected periurethrally might be a beneficial alternative, but there is a paucity of data on bulking therapy. Read More

View Article

Download full-text PDF

Source
September 2018
8 Reads

Trends in surgical management and pre-operative urodynamics in female medicare beneficiaries with mixed incontinence.

Neurourol Urodyn 2017 02 17;36(2):422-425. Epub 2015 Dec 17.

Department of Healthcare Policy and Research, New York-Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York.

Objective: We sought to examine the surgical trends and utilization of treatment for mixed urinary incontinence among female Medicare beneficiaries.

Methods: Data was obtained from a 5% national random sample of outpatient and carrier claims from 2000 to 2011. Included were female patients 65 and older, diagnosed with mixed urinary incontinence, who underwent surgical treatment identified by Current Procedural Terminology, Fourth Edition (CPT-4) codes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/nau.22946DOI Listing
February 2017
30 Reads

Current interventional management of male stress urinary incontinence following urological procedures.

Cent European J Urol 2015 26;68(3):340-7. Epub 2015 Sep 26.

Department of Urology, Collegium Medicum at the Jagiellonian University, Cracow, Poland.

Introduction: Despite improvements in surgical techniques and implementation of minimally invasive procedures, male stress urinary incontinence affects a substantial number of patients after prostatic surgery. In response to increasing demand of optimal treatment modality, new alternatives to artificial urinary sphincter have recently been introduced. This review summarises the therapeutic surgical options with their outcomes in management of postprostatectomy stress incontinence. Read More

View Article

Download full-text PDF

Source
http://www.termedia.pl/Journal/-57/pdf-25862-10?filename=17.
Web Search
http://www.termedia.pl/Current-interventional-management-of-
Publisher Site
http://dx.doi.org/10.5173/ceju.2015.616DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643709PMC
November 2015
33 Reads

Polyacrylamide hydrogel (Bulkamid®) for stress urinary incontinence in women: a systematic review of the literature.

Int Urogynecol J 2016 Mar 26;27(3):367-75. Epub 2015 Jul 26.

Department of Obstetrics and Gynaecology, Urogynaecology Unit, St. George's University Hospitals NHS Foundation Trust, London, SW17 0QT, UK.

Introduction And Hypothesis: Polyacrylamide hydrogel (PAHG, Bulkamid®) is one of several injectable agents currently used for the treatment of women with urinary stress incontinence. Although bulking agents appear to have lower efficacy rates compared to other surgical treatments, current evidence based on large prospective or comparative studies as well as systematic reviews is limited. The purpose of this study was to conduct a systematic review on the efficacy of PAHG in the treatment of female patients with stress urinary incontinence with regard to reproducibility, feasibility, safety and clinical outcome. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00192-015-2781-y
Publisher Site
http://dx.doi.org/10.1007/s00192-015-2781-yDOI Listing
March 2016
13 Reads

An Open Multicenter Study of Clinical Efficacy and Safety of Urolastic, an Injectable Implant for the Treatment of Stress Urinary Incontinence: One-Year Observation.

Biomed Res Int 2015 20;2015:851823. Epub 2015 Apr 20.

2nd Department of Gynecology, Medical University of Lublin, Ulica Jaczewskiego 8, 20-954 Lublin, Poland.

The prevalence of stress urinary incontinence rises and affects up to 30% of women after 50 years of age. Midurethral slings are currently the mainstay of surgical anti-incontinence therapy. Some patients experience recurrent SUI (RSUI) which is defined as a failure of anti-incontinence surgery after a period of time or persistence of SUI after the procedure aimed at correcting it. Read More

View Article

Download full-text PDF

Source
http://www.hindawi.com/journals/bmri/2015/851823/
Publisher Site
http://dx.doi.org/10.1155/2015/851823DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461699PMC
March 2016
18 Reads

[Bulking agents in the treatment of the stress urinary incontinence - current state and future perspectives].

Ceska Gynekol 2015 Mar;80(2):156-60

A review focused on minimally invasive treatment of the stress urinary incontinence using bulking agents provides a summary of the current knowledge on this subjects. This paper summarizes the findings on the mechanism of action, indications and applications technique, as well as clinical data on the efficacy and safety of the currently available bulking agents. Attention is also paid to possible future trends of this method. Read More

View Article

Download full-text PDF

Source
March 2015
6 Reads

Urethral bulking agents versus other surgical procedures for the treatment of female stress urinary incontinence: a systematic review and meta-analysis.

Eur J Obstet Gynecol Reprod Biol 2015 Jun 28;189:48-54. Epub 2015 Mar 28.

Department of Obstetrics and Gynaecology, University of Insubria, Varese, Italy. Electronic address:

Bulking agents provide an alternative option in the management of women with stress urinary incontinence and they seem to have an important role in the management flow chart of SUI. However, evidence on this issue is scanty. The most important aspect is to understand whether bulking agents are comparable with the other first-line anti-incontinence surgical procedure (MUS, Burch colposuspension and pubovaginal slings). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejogrb.2015.03.025DOI Listing
June 2015
77 Reads
1.627 Impact Factor

Collagenoma and voiding dysfunction as complications of periurethral bulking.

Int Urogynecol J 2015 Jul 10;26(7):1077-8. Epub 2015 Mar 10.

McGill University Health Centre, sponsored scholarship by King Fahad Medical City, Riyadh, Saudi Arabia.

Peri-urethral bulking agents are used as a management option for selected patients with stress urinary incontinence (SUI). We present a case of urinary retention and a large firm para-urethral vaginal mass as a complication of peri-urethral collagen injections 3 years before presentation. The patient was managed successfully with complete surgical resection of the mass. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00192-015-2649-1DOI Listing
July 2015
7 Reads

What's New in the Toolbox for Constipation and Fecal Incontinence?

Authors:
Yeong Yeh Lee

Front Med (Lausanne) 2014 24;1. Epub 2014 Mar 24.

School of Medical Sciences, Universiti Sains Malaysia , Kota Bharu , Malaysia ; Section of Gastroenterology and Hepatology, Department of Medicine, Medical College of Georgia, Georgia Regents University , Augusta, GA , USA.

Constipation and fecal incontinence (FI) are common complaints predominantly affecting the elderly and women. They are associated with significant morbidity and high healthcare costs. The causes are often multi-factorial and overlapping. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fmed.2014.00005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4335388PMC
February 2015
4 Reads

Injection devices for bulking agents in uro-gynaecology.

Arch Ital Urol Androl 2014 Sep 30;86(3):205-7. Epub 2014 Sep 30.

Urology Clinic, A.O.U.I. Verona.

Stress urinary incontinence (SUI) affects a large proportion of middle-aged and elderly women. When all conservative means are ineffective, a surgical treatment including retropubic suspension, pubovaginal and tension-free slings, is contemplated. Intra-urethral injections with bulking agents have been used as an alternative to the mentioned surgical procedures with alternate results. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4081/aiua.2014.3.205DOI Listing
September 2014
20 Reads

Comments to "perianal injectable bulking agents as treatment for faecal incontinence in adults".

Authors:
D F Altomare

Tech Coloproctol 2014 Nov 27;18(11):1139-40. Epub 2014 Sep 27.

Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10151-014-1218-9DOI Listing
November 2014
7 Reads

Current and emerging treatment options for fecal incontinence.

Authors:
Satish S C Rao

J Clin Gastroenterol 2014 Oct;48(9):752-64

Department of Medicine, Section of Gastroenterology/Hepatology, Digestive Health Center, Medical College of Georgia, Georgia Regents University, Augusta, GA.

Fecal incontinence (FI) is a multifactorial disorder that imposes considerable social and economic burdens. The aim of this article is to provide an overview of current and emerging treatment options for FI. A MEDLINE search was conducted for English-language articles related to FI prevalence, etiology, diagnosis, and treatment published from January 1, 1990 through June 1, 2013. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MCG.0000000000000180DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166012PMC
October 2014
12 Reads

Long-term efficacy of NASHA Dx injection therapy for treatment of fecal incontinence.

Neurogastroenterol Motil 2014 Aug 19;26(8):1087-94. Epub 2014 May 19.

Division of Colon & Rectal Surgery, University of Illinois, Chicago, IL, USA.

Background: Injectable bulking treatment for fecal incontinence (FI) is intended to expand tissue in the anal canal and prevent fecal leakage. Use of injectable bulking agents is increasing because it can be performed in an outpatient setting and with low risk for morbidity. This study evaluated the long-term (36-month) clinical effectiveness and safety of injection of non-animal stabilized hyaluronic acid/dextranomer (NASHA Dx) on FI symptoms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/nmo.12360DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4371654PMC
August 2014
20 Reads

Endoscopic treatment of vesicoureteral reflux with non-simultaneous involuntary detrusor contraction in chronic spinal cord injury patients with neurogenic detrusor overactivity.

Urol Int 2014 12;93(4):399-402. Epub 2014 Mar 12.

Department of Urology, Hospital Nacional de Parapléjicos, Toledo, Spain.

Objective: To analyze whether it is correct to use endoscopic treatment via bulking agents of vesicoureteral reflux (VUR) seen on video urodynamics with non-simultaneous involuntary detrusor contraction in chronic spinal cord injury (SCI) patients with neurogenic detrusor overactivity (NDO).

Methods: A retrospective study was performed with a cohort of 76 patients (age 48.9 ± 14. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000357440DOI Listing
August 2015
76 Reads

New treatments for fecal incontinence: update for the gastroenterologist.

Authors:
Arnold Wald

Clin Gastroenterol Hepatol 2014 Nov 15;12(11):1783-8. Epub 2014 Feb 15.

Division of Gastroenterology and Hepatology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. Electronic address:

Fecal incontinence is one of the most emotionally devastating of all nonfatal conditions. Many patients do not respond satisfactorily to conservative measures, and there is a need for new and effective strategies when medical therapy fails. The development of sacral nerve stimulation and other forms of neuromodulation and the injection of biologically compatible substances into the anal sphincter complex have brought renewed enthusiasm for using these novel treatments in this underserved population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cgh.2014.02.013DOI Listing
November 2014
6 Reads